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ABSTRACT Human cytomegalovirus (HCMV) is a betaherpesvirus that is a signifi-
cant pathogen within newborn and immunocompromised populations. Morbidity as-
sociated with HCMV infection is the consequence of viral dissemination. HCMV has
evolved to manipulate the host immune system to enhance viral dissemination and
ensure long-term survival within the host. The immunomodulatory protein vCXCL-1,
a viral chemokine functioning primarily through the CXCR2 chemokine receptor, is
hypothesized to attract CXCR2 neutrophils to infection sites, aiding viral dissemina-
tion. Neutrophils harbor HCMV in vivo; however, the interaction between vCXCL-1
and the neutrophil has not been evaluated in vivo. Using the mouse model and
mouse cytomegalovirus (MCMV) infection, we show that murine neutrophils harbor
and transfer infectious MCMV and that virus replication initiates within this cell type.
Utilizing recombinant MCMVs expressing vCXCL-1 from the HCMV strain (Toledo), we
demonstrated that vCXCL-1 significantly enhances MCMV dissemination kinetics.
Through cellular depletion experiments, we observe that neutrophils impact dissemi-
nation but that overall dissemination is largely neutrophil independent. This work
adds neutrophils to the list of innate cells (i.e., dendritic and macrophages/mono-
cytes) that contribute to MCMV dissemination but refutes the hypothesis that neu-
trophils are the primary cell responding to vCXCL-1.
IMPORTANCE An adequate in vivo analysis of HCMV’s viral chemokine vCXCL-1 has
been lacking. Here we generate recombinant MCMVs expressing vCXCL-1 to study
vCXCL-1 function in vivo using MCMV as a surrogate. We demonstrate that vCXCL-1
increases MCMV dissemination kinetics for both primary and secondary dissemina-
tion. Additionally, we provide evidence, that the murine neutrophil is largely a by-
stander in the mouse’s response to vCXCL-1. We confirm the hypothesis that
vCXCL-1 is a HCMV virulence factor. Infection of severely immunocompromised mice
with MCMVs expressing vCXCL-1 was lethal in more than 50% of infected animals,
while all animals infected with parental virus survived during a 12-day period. This
work provides needed insights into vCXCL-1 function in vivo.
KEYWORDS betaherpesvirus, neutrophils, vCXCL-1, viral chemokines,
cytomegalovirus, MCMV
Human cytomegalovirus (HCMV) is a serious pathogen in immunocompromisedpopulations (1, 2) and the leading cause of infectious congenital disease (3, 4).
Following in utero infection, fetal abnormalities such as microcephaly or other sequelae
(e.g., progressive deafness and learning disabilities) can occur (5, 6). Primary infection
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or latent viral reactivation in immunocompromised adults (7, 8), such as cancer therapy
patients, organ transplant recipients, or HIV/AIDS patients, can cause gastroenteritis,
retinitis, or organ transplant rejection (2, 9). Regardless of the host, disease due to viral
infection results from viral dissemination (10). Interestingly, HCMV has evolved numer-
ous immunomodulatory proteins that blunt normal protective immune responses,
restructure inflammatory environments, and ensure long-term survival in the host
(11–13). The viral chemokine, vCXCL-1, is an HCMV protein that preferentially recruits
CXCR2 neutrophils over other innate immune cells in vitro (14–16).
In addition to engaging CXCR2 (14, 15), vCXCL-1 may also signal through human
CXCR1 and CX3CR1 (15, 16). CX3CR1/CXCR1 natural killer (NK) cells functionally
respond to vCXCL-1 albeit at a significantly reduced level compared to CXCR2/
CXCR1 neutrophils (16). Unfortunately, any in vivo evaluation of the interaction of
vCXCL-1 with the immune system and its contribution to CMV pathogenesis has been
complicated by the species specificity of CMV (17–19).
Mouse cytomegalovirus (MCMV) infection of mice is frequently used to study CMV
dissemination. MCMV has similar pathogenesis to HCMV, contains many homologues
and orthologues to HCMV genes, and disseminates via innate immune cells (20, 21).
MCMV does not encode vCXCL-1 but rather encodes a C-C chemokine, MCK2, that
enhances dissemination (22–24). We have previously expressed vCXCL-1 from chim-
panzee CMV in MCMV and observed no salivary gland dissemination (25, 26), poten-
tially due to inappropriate timing and expression levels of the vCXCL-1 insert. Here, we
engineered human vCXCL-1 from the HCMV Toledo strain (vCXCL-1Tol) with a 2A
peptide linked to the MCMV chemokine MCK2 to ensure appropriate timing and
expression levels. We employed the MCMV bacmid of the Smith strain (pSM3fr-MCK2-
2fl) in which MCK2 aids viral entry in addition to its role in dissemination (24). Because
of MCK2’s dual role, we chose to fuse vCXCL-1Tol to MCK2 instead of deleting it from
the recombinant virus. We demonstrate that murine neutrophils are capable of har-
boring, transferring, and initiating MCMV replication and that CXCR2 stimulation is
sufficient to alter MCMV dissemination kinetics. Additionally, we show that infections
with recombinant MCMVs expressing vCXCL-1Tol exhibit increased viral dissemination
and virulence.
RESULTS
Murine neutrophils harbor, transfer, and initiate MCMV replication. The capac-
ity of neutrophils to impact cytomegalovirus dissemination is an area of contention. In
blood of immunosuppressed patients, neutrophils harbor the largest viral burden (27,
28) and transfer infectious HCMV ex vivo and in vitro, but they cannot support
productive viral replication (29, 30). The interaction between murine neutrophils and
MCMV has not been evaluated. Here we use a thioglycolate inflammation model (31)
to study the relationship between MCMV and murine neutrophils (Fig. 1A). Mice were
infected with an MCMV encoding green fluorescent protein (GFP) under the CMV
immediate early (IE) promoter (i.e., 4503) (22), and 4 h postinfection (Fig. 1B), total
peritoneal exudate was harvested and analyzed by flow cytometry. Peritoneal exudate
cells (PECs) in which virus has entered, uncoated, and expressed IE genes were
expected to become GFP positive (GFP). All live GFP cells were initially gated and
further analyzed for the presence of neutrophil (Ly6G) and myeloid/granulocyte
(CD11b) markers (Fig. 1B). Approximately 2% of all PECs were GFP, with roughly half
this population being CD11b. Further analysis of the CD11b subpopulation indicated
that 55% of these cells were Ly6G CD11b neutrophils and 45% were Ly6G
CD11b, likely dendritic cells or patrolling (resident) monocytes (32). The GFP CD11b
PECs could be susceptible cell types such as epithelial and fibroblastic cells but not T
or B cells (33). The gating strategy used to obtain these results is outlined (see Fig. S1B
in the supplemental material). To ensure that the GFP signal is from cells that were
infected and expressing GFP and not due to passive uptake or endocytosis of GFP
virions, we infected cultured fibroblasts and used the translational inhibitor cyclohex-
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imide (34) to demonstrate that GFP expression is de novo and not due to passive uptake
of GFP contamination in the viral preparation (Fig. S2).
We further evaluated the contribution of neutrophils to MCMV infection. Using
anti-Ly6G microbeads, a 97% pure neutrophil population was prepared from peritoneal
exudate from thioglycolate-treated, MCMV-infected mice (Fig. S1A). This population
included approximately 25% of the total GFP cells as described above. The remaining
population of peritoneal exudate cells (designated Flowthrough) represented 75% of
all the GFP cells. When both populations were assayed for viral genome via quanti-
tative PCR (qPCR) (Fig. 1C), we did not observe a significant difference in viral genome
content between the two populations, indicating that neutrophils and other cell
populations harbor MCMV genome 4 h postinfection (p.i.). As neutrophils are phago-
cytes and may be in the process of destroying virions, we carried out an infectious
center assay. Consistent with this notion, the Ly6G population had dramatically less
infectious MCMV compared with Flowthrough (Fig. 1D). To determine whether this
neutrophil population was capable of infecting a new host, isolated neutrophils were
adoptively transferred into uninfected immunocompetent mice. Three days after neu-
trophil transfer, blood was harvested and assayed for MCMV genome via qPCR. Transfer
FIG 1 Neutrophils harbor and transfer MCMV ex vivo and in vivo. (A) Experimental design. (B) PECs were evaluated for the presence of GFP-expressing virus.
Live GFP-expressing cells were gated for CD11b cells followed by Ly6-G gating. (C) Total DNA was extracted from 1 106 purified neutrophils or Flowthrough
cells. qPCR was performed to evaluate the number of MCMV genomes present. (D) Infectious center assay for determining the number of infected neutrophils.
A total of 1 106 purified neutrophils were incubated with an uninfected fibroblast monolayer for 5 days, and the number of plaques was evaluated. (E) MCMV
genomes were quantified from whole blood isolated from mice that were adoptively transferred 1 106 neutrophils from infected mice. Values are average
titers  standard deviations (SD) (error bars). Statistical significance was determined by Student’s t test and indicated as follows: ns, not significant; ***,
P 0.001.
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of infected neutrophils was sufficient to infect a new host (Fig. 1E), although it is
possible that a contaminating cell population could contribute this infectivity as well.
CXCR2 stimulation alters normal MCMV dissemination kinetics. Because vCXCL-
1Tol functions primarily through CXCR2 (14, 15, 35), we sought to understand whether
a targeted CXCR2 response could alter normal MCMV dissemination kinetics. When
mice are injected intraperitoneally (i.p.) with interleukin 17A (IL-17A), mesothelial cells
release host CXCL-1 (i.e., Gro) eliciting a neutrophilic, CXCR2-mediated response (36).
We confirmed reports that IL-17A treatment alters only the neutrophil population in the
peritoneum 4 h following treatment (data not shown). We exploited this experimental
setup to mimic the viral chemokine’s function in vivo and evaluate the contribution of
the vCXCL-1/CXCR2 signaling axis on viral dissemination (Fig. 2A). Mice treated with
IL-17A prior to i.p. infection with MCMV exhibited significantly greater viral burden in
spleen and lungs 5 days postinfection (dpi) compared to control animals treated with
vehicle control (Fig. 2B and C). IL-17A-treated animals also had greater levels of salivary
gland (SG)-associated virus seeding 5 dpi (Fig. 2D). Although there was faster seeding,
FIG 2 CXCR2 stimulation increases MCMV dissemination. (A) MCMV was administered i.p. during peak neutrophil response
induced with IL-17A or vehicle control (not treated). (B and C) Viral titers of whole-organ homogenates were determined
in the spleen (B) and lungs (C) of mice treated with IL-17A 5 days postinfection. n 3 with 4 or 5 mice per group. (D) The
salivary glands (SGs) of mice were harvested 5 days postinfection (dpi). Total DNA was harvested and subjected to qPCR
for total MCMV burden in the SG. (E) Depletion of neutrophils reduces IL-17A-enhanced MCMV dissemination to the spleen.
Plaque assays of spleens of mice 5 dpi. that received phosphate-buffered saline (PBS; i.e., vehicle), IL-17A alone,
neutrophil-depleting antibody (anti-Ly6G [Ly6G]) coupled with IL-17A treatment (IL-17A & Ly6G), or neutrophil-
depleting antibody alone prior to infection with MCMV. Data are from two pooled experiments. Data are normalized to the
mean PFU/gram of tissue of the PBS control for each experiment. Values are average titers  SD. Statistical significance
was determined by Student’s t test or one-way ANOVA with Tukey’s multiple comparison of means and indicated as
follows: *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001.
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IL-17A-treated animals did not exhibit a significant difference in viral titers within this
organ 14 dpi compared to control animals (data not shown).
Neutrophils were depleted 2 days prior to IL-17A treatment and MCMV infection,
then treated every other day after infection with anti-Ly6G or vehicle control (Fig. S3A).
The titers of the virus in the spleens were determined 5 dpi (Fig. 2E). Neutrophil
depletion resulted in a decreased viral burden in the spleens of IL17A-treated mice,
suggesting that in this inflammatory milieu, neutrophils play a role in dissemination
perhaps in addition to normal lymphatic drainage from the peritoneum (37).
Generation of recombinant MCMV expressing vCXCL-1Tol. We have previously
generated recombinant MCMVs that overexpress vCXCL-1 or host CXCL-1. These viruses
disseminated normally to the spleen, liver, and lung but were defective in SG dissem-
ination (25), leading to a hypothesis that levels and/or timing of chemokine expression
hindered SG dissemination. Therefore, we engineered a recombinant MCMV in which
vCXCL-1 from the HCMV Toledo strain (vCXCL-1Tol) was expressed as a cleavable fusion
protein with the MCMV chemokine, MCK2. A picornavirus 2A self-cleaving peptide
enabled the coexpression of the two chemokines (38) (Fig. 3A). The recombinant MCMV
was generated by coupling classical bacterial recombineering with bacterial artificial
chromosome from the Smith strain (pSM3fr-MCK2-2fl) (39) and CRISPR/Cas9 technol-
ogy. HindIII RFLP analysis confirmed galK insertion into pSM3fr-MCK2-2fl, resulting in a
1.5-kb size increase of the 7.1-kb band into the top of the triplet band (Fig. 3B, boxed
in red). The 500-bp addition of vCXCL-1Tol into the 7.1-kb band resulted in the creation
of a doublet in the middle band of the HindIII triplet (Fig. 3B). The supernatants of
FIG 3 Generation of recombinant MCMV expressing vCXCL-1Tol. (A) Bacterial artificial chromosome (BAC) schematic of vCXCL-1Tol insertion
into the mck2 locus. (B) HindIII RFLP analysis of the BACs. The triplet banding patterns are boxed in red. (C) Western blot analysis of the
viral supernatant of MCK2-2A-vCXCL-1Tol MCMV. (D) Single-step growth curve (MOI of 5.0). DPI, day postinfection. (E) Multistep growth
curves (MOI of 0.05). Values are average titers  SD (error bars).
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pSM3fr-MCK2-2fl-infected MEF 10.1 cells were subjected to Western blot analysis using
anti-FLAG antibodies to identify MCK2 and anti-HIS antibodies to identify vCXCL-1Tol
(Fig. 3C). Glycosylated MCK2 was detected at 40 kDa (40, 41) and vCXCL1 was
detected at 17 kDa (26). These data indicate the self-cleaving 2A-peptide efficiently
generated two independent proteins. In order to evaluate whether insertion of vCXCL-
1Tol alters replication in vitro, both single-step and multistep growth curves were
conducted (Fig. 3D and E). These analyses demonstrate that insertion of the vCXCL-1Tol
gene does not alter viral replication in vitro.
vCXCL-1Tol expression alters normal MCMV dissemination kinetics. To test the
hypothesis that vCXCL-1Tol alters normal dissemination, we infected BALB/c mice with
pSM3fr-MCK2-2fl expressing vCXCL-1Tol (called RMvCXCL-1Tol) compared to parental
pSM3fr-MCK2-2fl (Smith) and a rescued virus (called RMvCXCL-1Tol RQ). RQ has had the
MCK2-vCXCL1Tol fusion replaced with the pSM3fr-MCK2-2fl mck2 locus and serves as a
control for adventitious mutations that could have arisen during recombineering. In
addition, whole-genome sequencing was performed on recombinant MCMVs without
revealing any unexpected mutations (data not shown). Even though mice inoculated in
the footpad (FP) with recombinant MCMVs did not exhibit any difference in viral burden
at the site of inoculation 3 dpi (Fig. 4A), RMvCXCL-1Tol levels were 100-fold higher in
the popliteal lymph node at this time compared to either pSM3fr-MCK2-2fl or
RMvCXCL-1Tol RQ (Fig. 4B). Therefore, the addition of vCXCL-1Tol to MCMV does not
alter replication at the infection site, but it does increase the levels of virus in the
draining lymph node (LN). Importantly, vCXCL-1Tol expression dramatically increased
secondary dissemination to SG. Plaque assays of whole-organ homogenates revealed
FIG 4 Infection of mice with vCXCL-1Tol-expressing MCMVs increases primary and secondary dissemination. Mice were infected by
injecting 1 106 PFU of either virus Smith, RMvCXCL-1Tol, or RMvCXCL-1Tol RQ into their footpad (FP). (A to C) Plaque assays were
performed on FP (A), lymph nodes (LN) (B), and salivary glands (SG) (C) that were harvested 3 (FP and LN) and 14 (SG) dpi. n 3 to 5
experiments with at least three mice per group. Statistical significance was determined by one-way ANOVA with Tukey’s multiple
comparison of the means. (D and E) Mice were infected either intranasally (i.n.) (D) or intraperitoneally (i.p.) (E), and plaque assays were
performed on SG harvested 14 dpi. Results from two independent experiments with three or four mice per group are presented. Values
are average titers  SD (error bars). Statistical significance was determined by Student’s t test and indicated as follows: ns, not significant;
**, P 0.01; ****, P 0.0001.
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100-fold increased viral levels in SG at 14 dpi compared to either wild-type (WT) or RQ
viruses (Fig. 4C). These data indicate that vCXCL-1Tol significantly increases both
primary and secondary dissemination kinetics of MCK2-repaired pSM3fr bacmid-
derived virus.
It has been reported that different routes of inoculation produce different dissem-
ination patterns (32). To evaluate this possibility with our recombinant viruses, mice
were inoculated intranasally (i.n.) (Fig. 4D) or i.p. (Fig. 4E) with RMvCXCL-1Tol or Smith,
and SGs were harvested for plaque assays at 14 dpi. Regardless of the inoculation route,
expression of vCXCL-1Tol enhances MCMV SG dissemination and/or replication.
Analysis of cellular subsets responding to vCXCL-1Tol in vivo early during
infection. Because vCXCL-1Tol significantly increased dissemination independent of the
inoculation site, we evaluated leukocytes recruited to the inoculation site, draining LN,
and bloodstream following a FP infection early during infection to identify inflamma-
tory cells potentially contributing to increased dissemination. Mice were infected as in
Fig. 4, and FP, LN, and blood samples from infected animals were analyzed by flow
cytometry at 3 dpi. In the FP (Fig. 5A), expression of vCXCL-1Tol induced a significantly
higher neutrophil influx compared to control virus, without altering the levels of either
inflammatory monocytes (Ly6G Ly6Chi CD11b CD11c) or patrolling monocytes
(Ly6G Ly6Clo CD11b CD11c) (32). Within the draining LN, all three leukocyte
populations were significantly increased by vCXCL-1Tol compared to control (Fig. 5B),
while blood showed no difference (Fig. 5C). There was no difference in total leukocyte
influx into the LN and blood (Fig. S4). These data suggest that vCXCL-1 recruitment of
neutrophils to the infection site and draining LN or monocytes in LN could be
responsible for increased dissemination to SG.
Removal of specific cellular subsets reveals insights into vCXCL-1Tol function.
Using depleting antibodies, the importance of different cell types was tested. Neutro-
phil depletion with anti-Ly6G antibody prior to and during MCMV infection (Fig. 6A and
Fig. S3B) reduced the level of vCXCL-1-induced swelling to levels observed with control
virus in the absence of depletion (Fig. 6B). Neutrophil depletion also decreased to the
level of swelling in controls. Thus, the increase in swelling due to vCXCL-1Tol was
dependent on neutrophils. To examine whether neutrophil depletion alters viral bur-
den in different tissues, LNs were harvested from MCMV-infected mice that had either
been neutrophil depleted or left untreated, and virus titers in the draining LN were
determined 3 dpi (Fig. 6C). Neutrophil-depleted mice infected with RMvCXCL-1Tol had
less virus in the LN than non-neutrophil-depleted mice, but viral titers remained higher
than the viral titers in the controls. These data indicate that neutrophils are partially
responsible for vCXCL-1Tol-mediated dissemination, but they are not the major cell type
responding to vCXCL-1Tol.
vCXCL-1Tol increases virulence. Because there is no effective method for depleting
monocytes without depleting other cellular subsets (42), we infected NODSCIDIL-2
gamma chain-deficient (NSG) mice. These mice lack T, B, and NK cells and have
defective macrophages and dendritic cells (43). Although these mice are highly immu-
nodeficient, monocytes and neutrophils remain functional. The number of mice sur-
viving daily was recorded and plotted as a Kaplan-Meier survival curve (Fig. 7A).
Interestingly, many mice infected with RMvCXCL-1Tol died on or before 10 dpi, while all
mice infected with the control virus survived to 12 dpi at which point SGs and spleens
were harvested. These data indicate that vCXCL-1Tol is a virulence factor, as 58% of mice
infected with recombinant MCMVs expressing vCXCL-1Tol died compared to mice
infected with the Smith strain, which all survived. We also observed significantly higher
viral titers in the spleens of mice during infection with RMvCXCL-1Tol compared to the
control group (Fig. 7B), even though there was no difference in SG viral titer for mice
in both these groups at 12 dpi (Fig. 7C). These data point to either viral load in the
spleen, inflammatory infiltrates into the liver (Fig. S5), or another unknown effect of
vCXCL-1Tol as a determinant for mortality in NSG mice.
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As most HCMV infections are asymptomatic, studying its dissemination from primary
infection to the establishment of latency in humans has been limited to in vitro and ex
vivo analysis (1, 2). These studies revealed that innate immune cells are major reservoirs
of HCMV in blood and contribute to viral dissemination (28). HCMV’s reliance on innate
immune cells has resulted in the evolution of immunomodulatory proteins such as
chemokines that are capable of activating and recruiting innate immune cells (13). The
discovery of the HCMV chemokine vCXCL-1 led to the hypothesis that vCXCL-1 recruits
innate immune cells to the infection site and that these recruited cells contribute to
HCMV dissemination (29, 44, 45). An adequate in vivo analysis of vCXCL-1 function is
lacking. Here we employed a mouse model using recombinant MCMV expressing HCMV
vCXCL-1 in vivo. A major limitation of the MCMV model and the reason recombinant
MCMVs were generated is that some of the immunomodulatory proteins of MCMV and
FIG 5 vCXCL-1Tol alters cellular infiltrate in primary dissemination organs. Mice were infected via the footpads as in Fig. 4. (A to C) Footpads (A),
lymph nodes (B), and peripheral blood (C) were harvested 3 dpi and evaluated by flow cytometry. Cells were characterized as follows: neutrophils,
Ly6G CD11b; inflammatory monocytes (iMonocytes), Ly6G Ly6Chi CD11b CD11c; patrolling monocytes (pMonocytes), Ly6G Ly6Clo
CD11b CD11c. Values are average titers  SD (error bars). Statistical significance was determined by Student’s t test and indicated as follows:
ns, not significant; *, P 0.05; **, P 0.01.
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HCMV differ. MCMV encodes a C-C chemokine which also aids viral entry in MCMV
Smith strain (24). However, HCMV encodes C-C and C-X-C chemokines (13), enhancing
recruitment of multiple leukocyte subtypes (i.e., monocytes, neutrophils, and NK cells)
in vitro (15, 16, 46). vCXCL-1 attracts neutrophils and potentially NK cells (15, 16). These
observations suggest that neutrophils could be major players in HCMV dissemination.
To establish our model, we needed to understand MCMV-neutrophil interactions
and how/whether neutrophils have a role in MCMV dissemination. This is important
because neutrophils transfer HCMV (29), and vCXCL-1 alters human neutrophil func-
tions (15). We show in a thioglycolate-induced model that murine neutrophils harbor
and transfer MCMV to new cells although not as efficiently as other cells in the
Flowthrough. This could be due to the neutrophil’s shorter half-life ex vivo or to the fact
that neutrophils have phagocytosed viral genomes that are not infectious. We also
show that viral transcription/translation begins in neutrophils (i.e., GFP expression)
(Fig. 1), demonstrating that murine neutrophils can harbor MCMV.
Because vCXCL-1 is expressed late in HCMV’s life cycle (1), it is likely that infectious
viral particles are being released simultaneously with chemokine expression. Therefore,
we sought to mimic this environment. IL-17A injected i.p. into mice induces CXCL-1 (i.e.,
Gro) expression (36). CXCL-1 is a host chemokine that uses the CXCR2 receptor (47),
inducing primarily a neutrophilic influx into the peritoneal cavity. Stimulating the
CXCR2 signaling axis during infection increased viral burden in primary dissemination
organs (i.e., spleen and lungs) and resulted in increased SG seeding. However, IL-17A
treatment prior to infection did not lead to increased viral burden in SGs 14 dpi. This
potentially could be due to a variety of factors, including localization or longevity of
CXCR2 stimulation, as IL-17A treatment is transient. Therefore, it is not surprising that
IL-17A treatment impacted only primary dissemination. Interestingly, when neutrophils
were depleted from the IL-17A inflammation model, there was only a slight decrease in
viral burden compared to nondepleted animals. This points to another CXCR2 cell or
another chemokine/cytokine-responsive cell responding to IL-17A. While neutrophils
FIG 6 Neutrophils are partially responsible for vCXCL-1Tol-induced inflammation and dissemination. (A) Neutrophil depletion
experimental design. Ly6G, anti-Ly6G antibody; FP, footpad; LN, lymph node. (B) Footpad swelling of infected footpads up
to 3 dpi normalized to uninfected footpads. (C) Plaque assays were performed on LN harvested from depleted or control mice
at 3 dpi. Values are averages of two experiments with three mice per group. Bars represent the average titers SD (error bars).
Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparison of means and indicated as
follows: ***, P 0.001; ****, P 0.0001.
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are the only statistically significant population that changes in response to IL-17A (36;
data not shown), there could be a biologically relevant subset of CXCR2 cells (48–50)
responding to CXCL1 and aiding viral dissemination. It will be important to determine
what cell types (e.g., inflammatory monocytes, NK cells, macrophages, etc.) are becom-
ing infected immediately after IL-17A treatment.
Previously, we have demonstrated that overexpressing vCXCL-1 in the context of
MCMV infection did not change primary dissemination but inhibited secondary dis-
semination (25). We speculated that the timing and quantity of viral chemokine
expression induced an abnormal inflammatory environment, resulting in expedited or
premature viral clearance. To alleviate this concern, we generated a recombinant
MCMV expressing vCXCL-1 at relatively normal physiological times and levels by linking
it to the MCMV protein MCK2. When mice were infected with recombinant vCXCL-1Tol
MCMV, there was a significant difference in viral dissemination kinetics for both primary
and secondary dissemination compared to controls. Because different inoculation
routes have different dissemination mechanisms, it was important to determine
whether the phenotype observed was inoculation route dependent (32, 51). We
showed that the RMvCXCL-1Tol dissemination phenotype was still present whether
mice were inoculated by the more natural inoculation route (i.e., intranasal [51]) or the
more common intraperitoneal route. Because vCXCL-1Tol alters neutrophil functions
(15), murine neutrophils were depleted to dissect this relationship in vivo. As with
IL-17A neutrophil depletion, neutrophil depletion coupled with recombinant viral
infection significantly reduced viral dissemination but did not return viral burden to WT
MCMV levels. These data indicate that there is another cellular target through which
vCXCL-1Tol is functioning.
As monocytes have also been shown to express CXCR2 under certain conditions (48,
52), the next logical experiment would be to deplete monocytes. Unfortunately, specific
depletion of monocytes is not efficient (42). Instead, we chose to utilize the NSG mouse
FIG 7 vCXCL-1Tol increases virulence of MCMV in NSG mice which correlates with increased viral loads in the
spleen. (A) Kaplan-Meier survival curve comparing NSG mice infected with either RMvCXCL-1Tol or Smith MCMV. (B
and C) At the termination of the experiment (12 days postinfection), MCMV titers in the spleen (B) or SG (C) were
determined. Bars represent the average titers  SD (error bars). Each symbol shows the viral titer for an individual
mouse. Data are from three separate experiments with four to six mice per group for each virus. Statistical
significance was ascertained using the Student’s t test and indicated as follows: ns, not significant; ****, P 0.0001.
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model. These mice are highly immunocompromised and lack mature B, T, and NK cells
(43) and have defective macrophages and dendritic cells, which could participate in
MCMV dissemination (32, 51, 53). However, NSG mice have functional monocytes.
Because neutrophils were not the major cell type aiding dissemination (Fig. 6), we
hypothesized that if viral dissemination of vCXCL-1Tol-expressing recombinant MCMV
were still increased compared to WT MCMV in NSG mice, it would point toward a
monocytic response to vCXCL-1Tol. Surprisingly, infection of NSG mice with RMvCXCL-
1Tol and not strain Smith resulted in death (Fig. 7). This was not expected, but these
results support the claim that vCXCL-1Tol is a virulence factor (12, 15, 26, 54). Addition-
ally, Fig. 7 shows that primary dissemination (i.e., dissemination to the spleen) is
significantly different between the two viruses, but there is no difference in secondary
dissemination. This could indicate that primary dissemination and secondary dissemi-
nation are separate events mediated by different cell types, similar to our findings with
CXCL-1-overexpressing MCMVs (25).
While neutrophils are not the major cell type aiding dissemination, our results
provide evidence that murine neutrophils contribute to MCMV dissemination. We also
report that vCXCL-1Tol significantly enhances MCMV dissemination and pathogenesis.
However, the hypothesis that neutrophils are the sole responders to vCXCL-1Tol is
incorrect. Other CXCR2-positive cells such as monocytes (48, 52) and myeloid-derived
suppressor cells (55, 56) could be other targets for vCXCL-1. This hypothesis supports
previous findings in which monocytes are major drivers of CMV dissemination (1, 2, 32,
57). Interestingly, the deaths of NSG mice infected with vCXCL-1Tol MCMV provide
supporting evidence that this protein is a virulence factor albeit in NSG mice. We have
previously shown that vCXCL-1 from different HCMV strains vary in their ability to
activate and induce neutrophil recruitment (15), but now we have a system to test their
virulence in vivo.
MATERIALS AND METHODS
Plasmids. pCas9 was a gift from Luciano Marraffini (Addgene plasmid 42876) (58). The selectable
marker was replaced with kanamycin using Gibson Assembly. The p2A-Tol open reading frame (ORF) was
synthesized (Genscript) after adding the P2A sequence (Addgene). This plasmid contains 250 bp of MCK2
that is FLAG tagged followed by the 2A peptide and vCXCL-1 from the HCMV Toledo strain, which is 6
HIS tagged. pcDNA-MCMV IE1 was generated as a qPCR standard.
Cells and mice. All experiments were performed with low-passage (20) cells. Mouse embryonic
fibroblast 10.1 (MEF 10.1) (59) were cultured in Dulbecco modified Eagle medium (DMEM) (Corning)
supplemented with 10% Fetalclone III serum (HyClone, Logan, UT), 1% penicillin-streptomycin, and 1%
L-glutamine.
BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, ME) and housed under specific-
pathogen-free conditions. Four- to 5-week-old nonobese diabetic severe combined immunodeficient,
IL-2 common  chain null (NSG) mice were purchased from Jackson Laboratory (Bar Harbor, ME). The
Institutional Animal Care and Use Committees (IACUCs) at the University of Tennessee and University of
Cincinnati approved all animal procedures.
Viruses, BAC mutagenesis, and recombinant virus generation. RM4503 virus was a gift from Ed
Mocarski, Emory University (22), and MCMV Smith strain virus was derived from the pSM3fr-MCK2-2fl
bacterial artificial chromosome (BAC) (originally from B. Adler) was a gift from Chris Benedict (60). MCMV
was produced in vitro using MEF 10.1 cells. All viruses were stored at 80°C until use. Viral titer was
assessed by plaque assay (described below) on MEF 10.1 cells.
BAC mutagenesis was performed on pSM3fr-MCK2-2fl BAC by coupling galK recombineering (39)
with CRISPR/Cas9 technology. Briefly, Escherichia coli SW105 containing pSM3fr-MCK2-2fl was induced to
express lambda red recombinase, and galK was inserted into the MCK2 locus, resulting in pSM3fr-MCK2-
2fl-galK. SW105 cells containing pSM3fr-MCK2-2fl-galK were induced by heat and pCas9 with a gRNA
targeting galK along with a PCR product containing the MCK2-2A-vCXCL-1Tol DNA sequence was
transformed into them. Transformants were plated on chloramphenicol and kanamycin. The following
day, colonies were streaked onto MacConkey agar base (Difco) containing 1% galactose. Colonies that
retained the galK gene were pink, while transformants with the desired recombination were white.
SW105 cells containing recombinant BACs were further assessed via HindIII restriction fragment length
polymorphism (RFLP) analysis, and the 2A-Tol insert was sequenced via Sanger sequencing after PCR
amplification.
vCXCL-1Tol and control BACs were transfected into MEF 10.1 cells using LT1 transfection reagent
(Mirus). BAC origin excision was achieved through serial passage as previously described (61). Confir-
mation of loss of the BAC origin was assessed in purified viral particles instead of infected cells and then
evaluated with PCR. Approximately 10 serial passages were needed to effectively excise the BAC origin.
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Western blotting. Roller bottle (850 cm2) (Coring) supernatant from infected MEF 10.1 cells was
harvested at 100% cytopathic effect (CPE). Ni-NTA beads were used to purify 6 His proteins (vCXCL-1Tol)
and anti-FLAG agarose beads (Sigma) were used to purify FLAG-tagged proteins (MCK2) from approxi-
mately 60 ml of supernatant. Purified proteins were combined 1:1 with 6 His and FLAG. Proteins were
run on a 15% SDS-PAGE and blotted onto an AZURE Biosystems membrane. Anti-His and anti-FLAG
AZURE Western kits were used. Membranes were developed using an Odyssey Clx Li-Cor. Blots were
analyzed using Image Studio v4.0.
Sequencing and genome assembly. Sequencing was conducted as previously described (62).
Genome assembly was conducted with Geneious version 11.1.5. Briefly, purified viral DNA was harvested
using quick -gDNA miniprep kit (Zymo Research). The sequencing was designed to ensure a 40
genome coverage. Illumina sequencing reads (150 150 paired-end sequencing reads) were mapped to
the parental MCMV C5X reference genome (wild-type [WT] Smith strain). Geneious software’s SNP-
finding function was used to find mutations and single nucleotide polymorphisms (SNPs). All resequenc-
ing data are available from authors upon request.
qPCR MCMV quantification. SYBR green real-time quantitative PCR (qPCR) was performed to
measure viral load using primers designed to detect MCMV IE1 (63): IE1 Forward (5=-AGCCACCAACATT
GACCACGCAC-3=) and IE1 Reverse (5=-GCCCCAACCAGGACACACAACTC-3=). Copy number was standard-
ized using pcDNA-MCMV IE1. PCR was performed using a Chromo4 DNA engine PCR system (Bio-Rad).
Quantification of viral DNA (IE1) was carried out using MJ Opticon Monitor analysis software version 3.1.
Peritoneal inflammation models and neutrophil purification. Thioglycolate-induced peritoneal
inflammation was conducted as previously described (31). Briefly, mice were injected with 3% Brewer’s
thioglycolate (BD). Four hours after the mice were injected with BD, the mice were infected with 1 106 PFU
of MCMV. Three hours later, the mice were euthanized, and peritoneal exudate cells (PECs) were harvested.
Inflammation induced by IL-17A (Shenandoah Biotechnology Inc.) was performed as previously described (36).
Neutrophil purification was conducted using an anti-Ly6G microbead purification kit (Miltenyi
Biotec). Briefly, 9 or 10 mice were administered 3% thioglycolate, and PECs were harvested 4 h
postinjection. Peritoneal exudate was pooled from all mice, and the resulting single-cell suspension was
subjected to microbead purification. Purity was determined by flow cytometry.
Flow cytometry. For FP infections, feet (cut at the ankles) were minced into small pieces (3mm) and
incubated on a rotatory shaker at 37°C for 1 h in a 0.5% (wt/vol) solution of type I collagenase (Worthington).
The suspension of cells, LN, or PECs were passed through a 40-m cell strainer (Fisher Scientific). Red blood
cells were lysed with ACK (i.e., ammonium chloride-potassium) lysis buffer. Cells were stained for flow
cytometry analysis with the following fluorochrome-conjugated antibodies for cellular subsets: anti-Ly6G
(1A8), anti-Ly6C (HK1.4), anti-F4/80 (BM8), and anti-CD11c (N418) (all from BioLegend), anti-CD49b (DX5) from
eBioscience, and anti-CD11b (M1/70) from BD Pharmingen. Data were acquired on BD LSR II flow cytometer
(BD Biosciences) and analyzed using FlowJo software, version 10.1.
Neutrophil depletion. In vivo depletion of neutrophils was performed using 1A8 (anti-Ly6G)
(BioXcell) as previously described (64). Briefly, depleting antibodies were administered every day starting
at 2 days prior to MCMV infection or IL-17A treatment and then every other day until harvest. Neutrophils
were depleted using 0.25 mg/inoculation with anti-Ly6G. Flow cytometry was used to confirm depletion.
Plaque assay. Plaque formation assay on MEF 10.1 cells was used to determine viral titers in organs.
Briefly, MEF 10.1 cells were plated in a six-well dish. Organs were harvested and homogenized.
Homogenate was serially diluted and added to MEF 10.1 cells and incubated for 1 h. After incubation,
diluted virus was removed, and cells were overlaid with carboxylmethyl cellulose (CMC) medium and
incubated for 5 days. CMC was removed, and plates were stained with Coomassie blue.
Adoptive transfer of neutrophils. Four hours after i.p. thioglycolate injection, 9 or 10 mice were
infected i.p. with MCMV (RM4503) (22). Four hours postinfection, the mice were euthanized, and PECs
were isolated. Neutrophils were purified using MACs beads as described above. Neutrophils (1 106)
were injected into the footpads of naive mice, and the amount of MCMV in the blood was quantified
from 250 l of whole blood via qPCR at 3 days after transfer.
In vitro growth assay. MEF 10.1 cells were plated in triplicate in a six-well dish and infected with
Smith or RMvCXCL-1Tol recombinants for either a multistep (multiplicity of infection [MOI] of 0.05) or
single-step (MOI of 5) growth analysis. Supernatants were collected at the indicated times p.i. and
sonicated prior to assessing the titer. The titers of viruses were determined via plaque assay.
Infectious center assay. The infectious center assay was performed as previously described (65).
Briefly, PECs were harvested, and red blood cells were lysed with ACK lysis buffer. PECs or purified
neutrophils (1 106) were incubated for 12 h on an uninfected monolayer and overlaid with CMC
medium. Plaques were counted after 5 days.
Virulence studies. NSG mice (four to six animals per virus strain per experiment) were infected i.p.
with 5 105 PFU of either RMvCXCL-1Tol or Smith. Mice were monitored daily for weight loss and
administered supportive care if necessary. Mice were euthanized at day 12, SG and spleens were
removed, and virus titers in organs were determined by plaque assay.
Statistical analysis. Statistical significance was determined using Student’s t test or one-way analysis
of variance (ANOVA) with Tukey’s multiple comparison of means using Prism 7 (GraphPad Software, Inc.).
SUPPLEMENTAL MATERIAL
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